Compare VanEck Junior Gold Miners (GDXJ) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Junior Gold Miners vs Sanofi SA — how do they compare? VanEck Junior Gold Miners trades at $114.43 (market cap $8.22B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 11.6× VanEck Junior Gold Miners's market cap, and Sanofi SA pays a 6.01% dividend while VanEck Junior Gold Miners pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Junior Gold Miners for 41 Days and Sanofi SA for 94 Days on average.
| GDXJ | SNY | |
|---|---|---|
Market Cap | $8.22B | $95.18B |
Volume | 3,212,198 | 2,995,646 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $156.19 | $52.34 |
52-Week Low | $87.56 | $39.51 |
Typical Hold Time | 41 Days | 94 Days |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDXJ, the VanEck Junior Gold Miners ETF, trades at $114.39, up 4.81% in the last 24 hours. The technical outlook is bearish, with moving averages and key indicators like ADX signaling selling pressure. Recent news highlights multiple junior gold mining companies being added to the ETF's underlying index, potentially increasing its diversification and appeal. However, key financial ratios such as P/E and P/S are unavailable for direct analysis of the ETF's valuation.
The outlook for GDXJ is mixed, balancing recent index additions against a bearish technical backdrop. Investment opportunities lie in exposure to junior gold miners amid high gold prices, but risks include sector volatility and the ETF's current negative momentum. Investors should weigh the potential for broader market recognition against prevailing selling pressure.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
